Global Neuropathic Pain Market Opportunities and Forecast 2020-2027
- DLR2178
- 23 September, 2020
- Pharma & Healthcare
- Pages: 120
- Global
Global Neuropathic Pain Market, By Drug Class (Opioids, Steroids, Tricyclic Antidepressants, Capsaicin Cream), By Distribution Channel (Spinal Stenosis, Diabetic Neuropathy, Chemotherapy Induced Peripheral Neuropathy) opportunities and forecast 2020-2027
Market Overview
Neuropathic pain is chronic type of pain occurs owing to the tissue injury and is related with sensory-motor system. Rising prevalence of the diabetic neuropathy within region and growing healthcare expenditure are major drivers boosting market growth. However, growing counterfeit drugs and side effects of the treatments and the lack of awareness about neurological condition constrain growth of market.
The increasing prevalence of the diabetic neuropathy within region is anticipated to drive growth of market. For instance, as per study conducted by International Diabetes Federation (IDF) in 2016, it was projected that almost 420 million population of adult is suffering from the diabetes which is growing at rate of over 8.4% and is anticipated to reach over 625 million by 2040.
Diabetes leads to the diabetic neuropathy. Therefore an increase in diabetic population is major driving influence for growth of market. Moreover, increasing healthcare spending by many government and the non-governmental administrations in research has fuelled growth of market. Additionally, factors such as growing cases of the nerve pain, rising circumstances of the neuropathic pain owed to chemotherapy, the trauma from injury or the accidents by nerve damage, and growing penetration by the market players are leading to the growth of market
Segment Overview
Opioids are the most effective drugs for the management of pain. Furthermore, their use in management of the chronic pain and severe pain, which are related with the advanced medical illness, and is considered to be standard practice in most parts of the world. An agonist is a drug that triggers certain receptors in brain. Methadone (a strong) agonist therapy is effective treatment for the addiction to opioid drugs including heroin. These strong agonist opioids trigger opioid receptors, and once binding tightly, go through important conformational changes. These strong agonists include the codeine, heroin, fentanyl, hydrocodone, morphine, methadone, and oxycodoe.
In 2015, as per U.S. Department of Human and Health Services and the National Institutes of Health, over 25.4 million adults in America experience pain daily. The statistics indicates importance of the pain management and the impacts opioid segment positively.
Regional Overview
The North America is projected to dominate global market during forecast period. This is accredited to increase in geriatric population, leads to many diseases and disorders. Therefore, demand for market is predictable to increase. Similarly, well-developed infrastructure support in the North America and robust distribution network to raise market during the forecast period.
European market for neuropathic pain is anticipated to be second-largest during forecast period. Growing cases of cancer patients selecting for chemotherapy, in turn is expected to surge the demand for the neuropathic pain products is anticipated to boost growth of market in this region.
Additionally, companies operating in market are mainly focusing on the mergers and acquisition, anticipated to support the market growth. Asia-Pacific is projected to be fastest-growing market owed to increasing demand for the NSAIDs and the antidepressants drug and growing research on increasing herbal supplements to lessen the side effects.
Competitor overview
The market is extremely competitive in nature, and the major competitor are focusing on building awareness regarding neuropathic pain industry. Key players in market host seminars and exhibition to promote and display the use of operational medicines for varied medical applications. The projecting players in market have implemented various strategies for the development, such as product launches & approvals, product innovation, and investment in the R&D for advancements.
Key Players
Market Segmentation
By Drug Class
Market Overview
Neuropathic pain is chronic type of pain occurs owing to the tissue injury and is related with sensory-motor system. Rising prevalence of the diabetic neuropathy within region and growing healthcare expenditure are major drivers boosting market growth. However, growing counterfeit drugs and side effects of the treatments and the lack of awareness about neurological condition constrain growth of market.
The increasing prevalence of the diabetic neuropathy within region is anticipated to drive growth of market. For instance, as per study conducted by International Diabetes Federation (IDF) in 2016, it was projected that almost 420 million population of adult is suffering from the diabetes which is growing at rate of over 8.4% and is anticipated to reach over 625 million by 2040.
Diabetes leads to the diabetic neuropathy. Therefore an increase in diabetic population is major driving influence for growth of market. Moreover, increasing healthcare spending by many government and the non-governmental administrations in research has fuelled growth of market. Additionally, factors such as growing cases of the nerve pain, rising circumstances of the neuropathic pain owed to chemotherapy, the trauma from injury or the accidents by nerve damage, and growing penetration by the market players are leading to the growth of market
Segment Overview
Opioids are the most effective drugs for the management of pain. Furthermore, their use in management of the chronic pain and severe pain, which are related with the advanced medical illness, and is considered to be standard practice in most parts of the world. An agonist is a drug that triggers certain receptors in brain. Methadone (a strong) agonist therapy is effective treatment for the addiction to opioid drugs including heroin. These strong agonist opioids trigger opioid receptors, and once binding tightly, go through important conformational changes. These strong agonists include the codeine, heroin, fentanyl, hydrocodone, morphine, methadone, and oxycodoe.
In 2015, as per U.S. Department of Human and Health Services and the National Institutes of Health, over 25.4 million adults in America experience pain daily. The statistics indicates importance of the pain management and the impacts opioid segment positively.
Regional Overview
The North America is projected to dominate global market during forecast period. This is accredited to increase in geriatric population, leads to many diseases and disorders. Therefore, demand for market is predictable to increase. Similarly, well-developed infrastructure support in the North America and robust distribution network to raise market during the forecast period.
European market for neuropathic pain is anticipated to be second-largest during forecast period. Growing cases of cancer patients selecting for chemotherapy, in turn is expected to surge the demand for the neuropathic pain products is anticipated to boost growth of market in this region.
Additionally, companies operating in market are mainly focusing on the mergers and acquisition, anticipated to support the market growth. Asia-Pacific is projected to be fastest-growing market owed to increasing demand for the NSAIDs and the antidepressants drug and growing research on increasing herbal supplements to lessen the side effects.
Competitor overview
The market is extremely competitive in nature, and the major competitor are focusing on building awareness regarding neuropathic pain industry. Key players in market host seminars and exhibition to promote and display the use of operational medicines for varied medical applications. The projecting players in market have implemented various strategies for the development, such as product launches & approvals, product innovation, and investment in the R&D for advancements.
Key Players
- Eli Lilly and Company
- Astellas Pharma Inc.
- Biogen Inc.
- Baxter Healthcare Corporation
- Pfizer, Inc.
- Sanofi S.A
- Abbott Laboratories
- AstraZeneca
- Johnson & Johnson Services Inc.
- GlaxoSmithKline Plc.
Market Segmentation
By Drug Class
- Capsaicin Cream
- Tricyclic Antidepressants
- Opioids
- Steroids
- Others
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
- North America
- US
- Canada
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- UAE
- Rest of LAMEA
1 Executive Summary 21
2 Market Introduction 24
- 2.1 Scope of Study 25
- 2.2 Research Objective 25
- 2.3 List of Assumptions 25
- 2.4 Market Structure 26
3 Research Methodology 27
- 3.1 Research Process 28
- 3.2 Primary Research 29
- 3.3 Secondary Research 30
- 3.4 Market Size Estimation 31
- 3.5 Forecast Model 31
4 Market Dynamics 32
- 4.1 Introduction 33
- 4.2 Drivers 34
- 4.2.1 Rising prevalence of diabetic neuropathy within the region 34
- 4.2.2 Increasing healthcare expenditure 34
- 4.3 Restraints 35
- 4.3.1 Increasing counterfeit drugs & side effects of therapeutic treatments 35
- 4.3.2 Lack of awareness about the neurological condition 35
- 4.4 Opportunities 36
- 4.4.1 Growing government funding for healthcare 36
5 Market Factor Analysis 37
- 5.1 Porter’s Five Forces Model 38
- 5.1.1 Bargaining Power of Suppliers 38
- 5.1.2 Bargaining Power of Buyers 39
- 5.1.3 Threat of New Entrants 39
- 5.1.4 Threat of Substitutes 39
- 5.1.5 Intense Rivalry 39
- 5.2 Value chain analysis 40
- 5.2.1 R&D 40
- 5.2.2 Manufacturing 40
- 5.2.3 Distribution & Sales 40
- 5.2.4 Post-Sales Monitoring 40
6 Global Neuropathic Pain Market, By Type 41
- 6.1 Overview 42
- 6.1.1 Peripheral Neuropathy 43
- 6.1.2 Entrapment Neuropathy 43
- 6.1.3 Phantom Limb Pain 44
- 6.1.4 Trigeminal Neuralgia 44
- 6.1.5 Post Herpetic Neuralgia (PHN) 45
- 6.1.6 Post Traumatic Neuropathy 45
7 Global Neuropathic Pain Market, By Indication 46
- 7.1 Overview 47
- 7.2 Diabetic Neuropathy 48
- 7.3 Chemotherapy Induced Peripheral Neuropathy 49
- 7.4 Spinal Stenosis 49
8 Global Neuropathic Pain Market, By Diagnosis 50
- 8.1 Overview 51
- 8.2 Imaging 52
- 8.3 Physical Examination 53
- 8.4 Blood Tests 53
9 Global Neuropathic Pain Market, By Treatment 54
- 9.1 Overview 55
- 9.2 Medication 56
- 9.2.1 Medication Type 56
- 9.2.1.1 NSAIDs Type 57
- 9.2.1.2 Nerve Blocks Type 57
- 9.2.1.3 Antidepressant Drugs Type 57
- 9.2.1 Medication Type 56
10 Global Neuropathic Pain Market, By Distribution Channel 59
- 10.1 Overview 60
- 10.2 Retail Pharmacies & Drug Stores 61
- 10.3 Online Pharmacies 61
11 Global Neuropathic Pain Market, By End-User 62
- 11.1 Overview 63
- 11.2 Hospitals 64
- 11.3 Clinics 64
- 11.4 Research Organizations 65
12 Global Neuropathic Pain Market, By Region 66
- 12.1 Introduction 67
- 12.2 Americas 68
- 12.2.1 North America 73
- 12.2.2 US 77
- 12.2.3 Canada 80
- 12.2.4 South America 83
- 12.3 Europe 86
- 12.3.1 Western Europe 90
- 12.3.2 Germany 94
- 12.3.3 UK 97
- 12.3.4 France 100
- 12.3.5 Spain 103
- 12.3.6 Italy 106
- 12.3.7 Rest of Western Europe 109
- 12.3.8 Eastern Europe 112
- 12.4 Asia Pacific 116
- 12.4.1 China 120
- 12.4.2 Japan 123
- 12.4.3 India 126
- 12.4.4 Australia 129
- 12.4.5 Rest of Asia Pacific 132
- 12.5 Middle East & Africa 136
- 12.5.1 The Middle East 137
- 12.5.1.1 United Arab Emirates 142
- 12.5.1.2 Saudi Arabia 145
- 12.5.1.3 Oman 148
- 12.5.1.4 Kuwait 151
- 12.5.1.5 Qatar 154
- 12.5.1.6 Egypt 157
- 12.5.1.7 Jordan 160
- 12.5.1.8 Iran 163
- 12.5.1.9 Iraq 166
- 12.5.1.10 Lebanon 169
- 12.5.2 Africa 172
- 12.5.2.1 South Africa 176
- 12.5.2.2 Morocco 179
- 12.5.2.3 Tunisia 182
- 12.5.2.4 Algeria 185
- 12.5.3 Rest of Middle East & Africa 188
- 12.5.1 The Middle East 137
13 Company Landscape 192
- 13.1 Company Market Share Analysis 193
- 13.1.1 Introduction 193
- 13.2 Competitive Landscape 194
- 13.2.1 Introduction 194
- 13.3 Key Developments 195
14 Company Profile 197
- 14.1 Sanofi 198
- 14.1.1 Company Overview 198
- 14.1.2 Financial Overview 198
- 14.1.3 Products Offering 199
- 14.1.4 Key Developments 199
- 14.1.5 SWOT Analysis 199
- 14.1.6 Key Strategy 199
- 14.2 Pfizer Inc. 200
- 14.2.1 Company Overview 200
- 14.2.2 Financial Overview 200
- 14.2.3 Products Offering 201
- 14.2.4 Key Developments 201
- 14.2.5 SWOT Analysis 201
- 14.2.6 Key Strategy 201
- 14.3 Abbott Laboratories 202
- 14.3.1 Company Overview 202
- 14.3.2 Financial Overview 202
- 14.3.3 Products Offering 203
- 14.3.4 Key Developments 203
- 14.3.5 SWOT Analysis 203
- 14.3.6 Key Strategy 203
- 14.4 GlaxoSmithKline Plc (GSK) 204
- 14.4.1 Company Overview 204
- 14.4.2 Financial Overview 204
- 14.4.3 Products Offering 205
- 14.4.4 Key Developments 205
- 14.4.5 SWOT Analysis 205
- 14.4.6 Key Strategy 205
- 14.5 Eli Lilly and Company 206
- 14.5.1 Company Overview 206
- 14.5.2 Financial Overview 206
- 14.5.3 Products Offering 207
- 14.5.4 Key Developments 207
- 14.5.5 SWOT Analysis 207
- 14.5.6 Key Strategy 207
- 14.6 Johnson & Johnson Services Inc. 208
- 14.6.1 Company Overview 208
- 14.6.2 Financial Overview 208
- 14.6.3 Products Offering 209
- 14.6.4 Key Developments 209
- 14.6.5 SWOT Analysis 209
- 14.6.6 Key Strategy 209
- 14.7 Depomed Inc. 210
- 14.7.1 Company Overview 210
- 14.7.2 Financial Overview 210
- 14.7.3 Products Offering 210
- 14.7.4 Key Developments 211
- 14.7.5 SWOT Analysis 211
- 14.7.6 Key Strategy 211
- 14.8 AstraZeneca 212
- 14.8.1 Company Overview 212
- 14.8.2 Financial Overview 212
- 14.8.3 Products Offering 213
- 14.8.4 Key Developments 213
- 14.8.5 SWOT Analysis 213
- 14.8.6 Key Strategy 213
- 14.9 Astellas Pharma Inc. 214
- 14.9.1 Company Overview 214
- 14.9.2 Financial Overview 214
- 14.9.3 Products Offering 215
- 14.9.4 Key Developments 215
- 14.9.5 SWOT Analysis 215
- 14.9.6 Key Strategy 215
- 14.10 Biogen Inc. 216
- 14.10.1 Company Overview 216
- 14.10.2 Financial Overview 216
- 14.10.3 Products Offering 217
- 14.10.4 Key Developments 217
- 14.10.5 SWOT Analysis 217
- 14.10.6 Key Strategy 217
- 14.11 Baxter Healthcare Corporation 218
- 14.11.1 Company Overview 218
- 14.11.2 Financial Overview 218
- 14.11.3 Products Offering 219
- 14.11.4 Key Developments 219
- 14.11.5 SWOT Analysis 219
- 14.11.6 Key Strategy 219
15 Appendix 220
- 15.1 Discussion Blue Print 221
Report You Might be Interested
Choose License Type
- USD
- GBP
- EURO
- INR
